TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Flexion Ratio (FRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of MII eggs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Stenosis Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes of sympathetic skin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Score of Sino Nasal Outcome Test 22 (SNOT 22)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Framingham Risk Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline glycosylated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maintenance in Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Therapeutic Failures
Endpoint domain: Adverse events/effects
Primary endpoint: Constant total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change from baseline best-corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PS-ICU Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of intraoperative air leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events Related to Flortaucipir Administration
Endpoint domain: Adverse events/effects
Primary endpoint: Flortaucipir PET Scan SUVr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Driving Error Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in clinical circulatory state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uptake of FLT PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily night sweats frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily hot flashes frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean VAS score for hot flashes and night sweats
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of participants with functional independence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self report depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical activity level measured by wearing a monitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma analyte concentration (Cmax) of JNJ-42396302
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve for JNJ-42396302
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actual sampling time to reach the maximum plasma analyte concentration (tmax) of JNJ-42396302
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tau deposition over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Exceptional responders to chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Spectacle independency
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PC-MRI procedure reproducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final Infarct Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utility-weighted Modified Rankin Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Index of severity incontinence (ISI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incontinence quality of life (IQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Post-treatment Maximum Standardized Uptake Value (SUVmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological distress symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: proportion of patients with Grade 3 or above adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects experiencing dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: usability of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: intensity in Rehabilitation Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Major Pathological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in asthma control from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: IPA% (MPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPA% (PRU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent daily adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: therapeutic effects of far infrared radiation on HIV/AIDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural success of the resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Plasma concentrations achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal allograft injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sum pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change In Lactate Dehydrogenase (LDH) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Necrosis Factor Alpha (TNF-alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse event profile of patients undergoing PIPAC
Endpoint domain: Adverse events/effects
Primary endpoint: Dose limiting toxicities of PIPAC with oxaliplatin
Endpoint domain: Adverse events/effects
Primary endpoint: Lack of infection attributable to probiotic organisms
Endpoint domain: Adverse events/effects
Primary endpoint: Quantitative Myocardial F18-florbetapir Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With an Undetectable PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IKDC Subjective Knee Evaluation Score Change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of gastric peristalsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: One-carbon nutrient intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Peri-Procedural Myocardial Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients reaching target plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vitreous Haze Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of anal cancer
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants experiencing all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants experiencing treatment-emergent AEs
Endpoint domain: Adverse events/effects
Primary endpoint: % of WIC participant visits with EI/ECSE referral
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: % EI/ECSE referrals evaluated by EI/ECSE
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time from referral to evaluation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PTSD severity (PCL-6)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants Who Are Pain Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance in everyday living score change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall quality of colonoscopy prep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Atrial Stretching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Atrial Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse events including gestational complication or disease specific complication
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in eating disorders symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Total Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lymphedema severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of Cefazolin and Ondansetron in maternal blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in immunological markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Psoriasis symptom control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Seizure-free Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of objective responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serologic response to BNT162b2 vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Miles walked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Humoral Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy of diagnosing myometrial invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy of predicting lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Subjects Receiving no Opioid Rescue
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Quality of Life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: complete resection (R0) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Calf Muscle Atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of subjects with a NIHSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma Trough Concentrations (Ctrough) for Saquinavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to Twelve Hours (AUC0-12h) for Saquinavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events (AE) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of completion of QMBE intervention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: accuracy of Regadenoson to induce hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventilatory efficiency pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of diabetic nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Oseltamivir carboxylate maximum concentration (OC Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration curve 0-12h (OC AUC(0-12))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of DLT
Endpoint domain: Adverse events/effects
Primary endpoint: Disease Response Measured Objectively by MRI of Brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically indicated TLR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Memory span
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Soluble transferrin receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: vestibular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postural function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Score post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful nutritional rehabilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intra-operative and Postoperative Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Surgical Times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Variation of craving intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Complete Resection or Residual Tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Degree of evidence-based guideline-concordant care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic complete responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of the rate of exacerbations of herpes simplex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in the number of local complaints (pain, itching, burning, rash)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of contraction events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Vaccine virus particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oxygen supplementation period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adhesion recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Ease of Lens Handling for Insertion
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area Under the Concentration Time Curve From Zero to 24 Hours (AUC0-24h) of Total S-cortisol in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: VAS worst
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in ADAS-Cog-11
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resolution of IGF-1 Growth Hormone abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ACR 20% response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Total Sharp Score (TSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post sepsis mortality/re-admission
Endpoint domain: Mortality/survival
Primary endpoint: Prevention of influenza virus infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of check-ins with epinephrine auto-injector
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Keratometry in Diopters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: iGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference in respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Wrist angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hemoglobin (Hb) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Cartilage oligomeric matrix protein serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Knee Joint Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Best Overall Response Rate (BORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of allogenetic NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission induction as defined by PDAI score < 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of remission over 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of the newly developed device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean neonatal blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient survival at 28 days
Endpoint domain: Mortality/survival
Primary endpoint: frequency of T regulatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proximal Diminutive Adenoma Detection Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from Baseline salivary malondialdehyde level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attrition rate due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in overall function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PENN Alcohol Craving Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Roland-Morris Lower Back Pain Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Endothelial Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NIHSS Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: AngioRNM and/or AngioTC changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: emergence of major depressive episodes
Endpoint domain: Adverse events/effects
Primary endpoint: emergence of mania, hypomania, and mixed states
Endpoint domain: Adverse events/effects
Primary endpoint: GBMI baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GBMI120 - 139
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall lifting and tightening of the buttocks and thighs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to HBV vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Hemodynamical effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in SNAP-IV-P ADHD Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postsurgical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Columbia Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of granulocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of NK-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Children's Peer Relationships - Peer Report
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Children's Peer Relationships - Child Self-Report
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Children's Peer Relationships - Teacher Report
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: AUC0-24h, Cmax and tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apgar Score value below 7 after 5 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes